SCNI Dilution Risk Analysis: Scinai Immunotherapeutics Ltd.

Scinai Immunotherapeutics Ltd. (SCNI) carries a DilutionWatch dilution risk score of 77/100 — CRITICAL, calculated from real-time SEC EDGAR filing data across five dimensions: shelf registration capacity, ATM program activity, warrant overhang, cash runway estimate, and historical share count growth.

Key Risk Factors for SCNI

• Shelf registration capacity: Active S-3 or S-3/A filings indicate SCNI has pre-authorized equity offerings. Watch for 424B5 prospectus supplements — these mean an offering is executing now.
• ATM program activity: 424B3 filings indicate continuous share selling through an at-the-market program. These dilute shareholders daily with no formal offering announcement.
• Warrant overhang: Outstanding warrants represent shares that will be issued in the future — often at below-market prices when exercised.
• Cash runway: Biotech companies often have limited cash relative to burn rate. Under 6 months of runway almost guarantees a dilutive capital raise.
• Historical pattern: Share count growth over 1-3 years is the strongest predictor of future dilution. Check SCNI's outstanding share count trend on the live page.